2-[4-(3-(N,N-dimethyl)amino-phenoxy)-phenyl]-1H-benzoimidazole-5-carboxylic acid amide

ID: ALA3982788

PubChem CID: 10156124

Max Phase: Preclinical

Molecular Formula: C22H20N4O2

Molecular Weight: 372.43

Molecule Type: Small molecule

Associated Items:

This compound is not in our inventory system

Names and Identifiers

Canonical SMILES:  CN(C)c1cccc(Oc2ccc(-c3nc4cc(C(N)=O)ccc4[nH]3)cc2)c1

Standard InChI:  InChI=1S/C22H20N4O2/c1-26(2)16-4-3-5-18(13-16)28-17-9-6-14(7-10-17)22-24-19-11-8-15(21(23)27)12-20(19)25-22/h3-13H,1-2H3,(H2,23,27)(H,24,25)

Standard InChI Key:  COGXEORJSOQOLI-UHFFFAOYSA-N

Molfile:  

     RDKit          2D

 28 31  0  0  0  0  0  0  0  0999 V2000
    8.1736   -4.2285    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.6891   -3.5633    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.9119   -3.8158    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.9119   -4.6371    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.6891   -4.8938    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.2001   -3.4072    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.4882   -3.8158    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.4882   -4.6371    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.2001   -5.0498    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.7764   -3.4072    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.7764   -2.5859    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    4.0646   -3.8158    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.9949   -4.2285    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.4076   -3.5167    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.2289   -3.5167    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.6375   -4.2285    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.2289   -4.9403    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.4076   -4.9403    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.4588   -4.2285    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   11.8716   -4.9403    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.6929   -4.9403    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.1015   -5.6481    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.6929   -6.3599    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.8716   -6.3599    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.4588   -5.6481    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.9228   -5.6481    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   14.3355   -4.9403    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.3355   -6.3599    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  1  5  1  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  4  9  2  0
  3  6  2  0
 10 11  2  0
 10 12  1  0
  7 10  1  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 13 18  2  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 20 25  2  0
 19 20  1  0
 26 27  1  0
 26 28  1  0
 22 26  1  0
 16 19  1  0
  1 13  1  0
M  END

Associated Targets(Human)

CHEK2 Tchem Serine/threonine-protein kinase Chk2 (4015 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 372.43Molecular Weight (Monoisotopic): 372.1586AlogP: 4.19#Rotatable Bonds: 5
Polar Surface Area: 84.24Molecular Species: NEUTRALHBA: 4HBD: 2
#RO5 Violations: HBA (Lipinski): 6HBD (Lipinski): 3#RO5 Violations (Lipinski):
CX Acidic pKa: 11.08CX Basic pKa: 4.48CX LogP: 3.74CX LogD: 3.74
Aromatic Rings: 4Heavy Atoms: 28QED Weighted: 0.55Np Likeness Score: -1.37

References

1.  (2007)  2-phenyl benzimidazoles and imidazo-4,5|-pyridines as CDS1/CHK2-inhibitors and adjuvants to chemotherapy or radiation therapy in the treatment of cancer, 

Source